Back to Journals » OncoTargets and Therapy » Volume 9

BC200 LncRNA a potential predictive marker of poor prognosis in esophageal squamous cell carcinoma patients

Authors Zhao R, Zhu C, Li X, Cao W, Zong H, Cao X, Hu H

Received 28 October 2015

Accepted for publication 24 February 2016

Published 15 April 2016 Volume 2016:9 Pages 2221—2226

DOI https://doi.org/10.2147/OTT.S99401

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Lucy Goodman

Peer reviewer comments 2

Editor who approved publication: Dr William Cho


Rui-Hua Zhao,1,* Cai-hua Zhu,2,* Xiang-Ke Li,1 Wei Cao,3 Hong Zong,1 Xin-Guang Cao,2,4 Hai-Yan Hu5

1Department of Oncology, The First Affiliated Hospital of Zhengzhou University, 2Department of General Surgery, The Affiliated Cancer Hospital of Zhengzhou University, 3Department of Translational Medicine Center, Zhengzhou Center Hospital, 4Department of Digestive Disease, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 5Oncology Department, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of China

*These authors contributed equally to this work


Objective: To explore the expression and prognosis significance of BC200 in esophageal squamous cell carcinoma (ESCC) patients who received radical resection.
Methods: We used quantitative real-time polymerase chain reaction to detect the expression level of BC200 in cancer tissue and paired adjacent normal tissue samples from 70 ESCC patients who received radical surgical resection and analyzed the correlation of the relative expression level of BC200 with clinical-pathological features and prognosis.
Results: We found that the relative expression of BC200 was significantly higher in ESCC tissues compared with adjacent normal tissue samples (P=0.023). But the expression of BC200 were not related to clinical-pathological features, such as age, TNM stages, and histological grade (P>0.05). Kaplan–Meier analysis showed that high expression levels of BC200 were correlated with poor prognosis in ESCC patients. Patients with a high level of BC200 had a shorter disease-free survival and overall survival than those with low BC200 expression (P=0.034 and P=0.031, respectively). On multivariate analysis, the hazard ratio (HR) of BC200 expression was 2.17 (95% confidence interval [CI]=1.12–4.19, P=0.022) for disease-free survival and 2.24 (95% CI=1.12–4.49, P=0.023) for overall survival.
Conclusion: Our results indicate that high expression of BC200 reflects poor prognosis and could serve as a novel predictive marker for ESCC patients who received radical resection.

Keywords: BC200, esophageal squamous cell carcinoma, predictive marker, poor prognosis, long noncoding RNAs

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]